RESUMO

BACKGROUND: Chagas disease (ChD) is endemic in many parts of the world and can be transmitted through organ transplantation or reactivated by immunosuppression. Organs from infected donors are occasionally used for transplantation, and the best way of managing the recipients remains a subject of debate. METHODS: We present a single-center cohort study describing a 10-year experience of kidney transplantation in patients at risk of donor-derived ChD and or reactivation. Patients received prophylactic treatment with Benznidazole and were monitored for transmission or reactivation. Monitoring included assessing direct parasitemia, serology, and polymerase chain reaction (PCR). RESULTS: Fifty-seven kidney transplant recipients (KTRs) were enrolled in the study. Forty-four patients (77.2%) were at risk of primary ChD infection, nine patients (15.8%) were at risk of disease reactivation, and four patients (7.0%) were at risk of both. All patients received Benznidazole prophylaxis, starting on the first day after transplantation. Parasitemia was assessed in 51 patients (89.5%), serology also in 51 patients (89.5%), and PCR in 40 patients (70.2%). None of the patients exhibited clinically or laboratory-detectable signs of disease. A single patient experienced a significant side effect, a cutaneous rash with intense pruritus. At 1-year post-transplantation, the patient and graft survival rates were 96.5% and 93%, respectively. CONCLUSION: In this study, no donor-derived or reactivation of Trypanosoma cruzi infection occurred in KTRs receiving Benznidazole prophylaxis.

RESUMO

This study compares the humoral immune response of a cohort of renal transplant recipients (RTRs), in Trinidad & Tobago following two-dose primary immunization with non-mRNA vaccines amidst the COVID-19 pandemic. RTRs along with healthy, age-and gender-matched controls received either the adenoviral vector vaccine, AstraZeneca-Vaxzevria (AZ) or the inactivated vaccine, Beijing CNBG-BBIBP- CorV/Sinopharm (SP). Samples were taken after completion of a two-dose primary immunization during the period November 2021 to December 2021, at a mean interval of 138 days following immunization. 38/72 RTRs (53 %) failed to generate any protective antibody responses, compared with 7/73 participants, approximately 10 % in the healthy, age and gender-matched control group. In the RTRs, there was no significant correlation of their antibody concentration with either the timing of sample collection or the interval since transplantation. The study provides necessary information about the humoral response after two- doses of non-mRNA vaccines in a group of transplant recipients.

RESUMO

Torque Teno Virus (TTV) is a nonpathogenic and ubiquitous ssDNA virus, a member of the Anelloviridae family. TTV has been postulated as a biomarker in transplant patients. This study aimed to determine the TTV species diversity and variability in renal transplant recipients and to associate species diversity with the corresponding TTV viral load. From 27 recipients, 30 plasma samples were selected. Viral load was determined using two real-time PCR assays, followed by RCA-NGS and ORF1 phylogenetic analysis. The TTV diversity was determined in all samples. Variability was determined in three patients with two sequential samples (pre- and post-transplantation). Most of the samples presented multiple TTV species, up to 15 different species were detected. In the pre-transplant samples (n = 12), the most prevalent species were TTV3 (75%) and TTV13 (75%), and the median number of species per sample was 5 (IQR: 4-7.5). TTV3 was also the most prevalent (56%) in the post-transplant samples (n = 18), and the median number of species was 2 (IQR: 1.8-5.5). No significant correlation between the number of species and viral load was found. The number and type of TTV species showed total variability over time. We report high TTV species diversity in Argentinian recipients, especially in pre-transplant period, with total intra-host variability. However, we found no significant correlation between this high diversity and TTV viral load.

Assuntos

RESUMO

Abstract Background: End-stage renal diseases patients have a high risk of postoperative nausea and vomiting (PONV), which is multifactorial and need acute attention after renal transplantation for a successful outcome in term of an uneventful postoperative period. The study was done to compare the efficacy of palonosetron and ondansetron in preventing early and late-onset PONV in live donor renal transplantation recipients (LDRT). Methods: The prospective randomized double-blinded study was done on 112 consecutive patients planned for live donor renal transplantation. Patients of both sexes in the age group of 18-60 years were randomly divided into two groups: Group O (Ondansetron) and Group P (Palonosetron) with 56 patients in each group by computer-generated randomization. The study drug was administered intravenously (IV) slowly over 30 seconds, one hour before extubation. Postoperatively, the patients were accessed for PONV at 6, 24, and 72 hours using the Visual Analogue Scale (VAS) nausea score and PONV intensity scale. Results: The incidence of PONV in the study was found to be 30.35%. There was significant difference in incidence of PONV between Group P and Group O at 6 hours (12.5% vs. 32.1%, p = 0.013) and 72 hours (1.8% vs. 33.9%, p < 0.001), but insignificant difference at 24 hours (1.8% vs. 10.7%, p = 0.113). VAS-nausea score was significantly lower in Group P as compared to Group O at a time point of 24 hours (45.54 ± 12.64 vs. 51.96 ± 14.70, p = 0.015) and 72 hours (39.11 ± 10.32 vs. 45.7 ± 15.12, p = 0.015). Conclusion: Palonosetron is clinically superior to ondansetron in preventing early and delayed onset postoperative nausea and vomiting in live-related renal transplant recipients.

RESUMO

La enfermedad renal crónica (ERC) es un problema sanitario mundial que afecta al 10% de la población. Su prevalencia ha ido en aumento debido a factores relacionados con el estilo de vida y el envejecimiento de la población. Objetivo. Analizar la percepción de los pacientes receptores de trasplantes renales sobre su calidad de vida, y evaluar los factores que influyen en la calidad de vida post-trasplante renal. Metodología. Para ello, se llevó cabo un estudio bibliográfico considerando fuentes de bases de datos académicas como PubMed, Scopus, Web of Science, entre otras. Donde se usaron como descriptores de búsqueda "trasplante renal", "calidad de vida", "percepción del paciente", "resultados post-trasplante". Además, la búsqueda se amplió en revistas especializadas, tesis, libros y conferencias relacionadas con el tema. como criterios de inclusión fueron considerados estudios originales, revisiones sistemáticas, metaanálisis, publicaciones en los últimos 10 años, etc. Y como exclusión fueron considerados estudios no relacionados, artículos de opinión, publicaciones en idiomas no accesibles. En cuanto al proceso extracción de la información, se usó la matriz de registro y las técnicas de observación y análisis documental, la matriz quedo constituida por Autor(es), año de publicación, país de origen, objetivos del estudio, metodología utilizada, variables analizadas, resultados principales, y conclusiones relevantes. Conclusión. Es esencial reconocer que la calidad de vida post-trasplante renal es una experiencia subjetiva que varía significativamente entre los pacientes y que está influenciada por una amplia gama de factores, que van desde la gestión de síntomas físicos hasta el manejo de desafíos psicológicos y sociales.

Chronic kidney disease (CKD) is a worldwide health problem affecting 10% of the population. Its prevalence has been increasing due to factors related to lifestyle and population aging. Objective. To analyze the perception of renal transplant recipients on their quality of life, and to evaluate the factors that influence post renal transplant quality of life. Methodology. For this purpose, a bibliographic study was carried out considering sources of academic databases such as PubMed, Scopus, Web of Science, among others. The search descriptors used were "renal transplant", "quality of life", "patient perception", "post-transplant results". In addition, the search was extended to specialized journals, theses, books and conferences related to the subject. Inclusion criteria included original studies, systematic reviews, meta-analysis, publications in the last 10 years, etc. Unrelated studies, opinion articles, publications in non-accessible languages were considered as exclusion criteria. As for the information extraction process, the registration matrix and the techniques of observation and documentary analysis were used, the matrix was made up of author(s), year of publication, country of origin, objectives of the study, methodology used, variables analyzed, main results, and relevant conclusions. Conclusion. It is essential to recognize that post-renal transplant quality of life is a subjective experience that varies significantly among patients and is influenced by a wide range of factors, ranging from the management of physical symptoms to the management of psychological and social challenges.

A doença renal crônica (DRC) é um problema de saúde global que afeta 10% da população. Sua prevalência tem aumentado devido a fatores de estilo de vida e ao envelhecimento da população. Objetivo. Analisar a percepção dos receptores de transplante renal sobre sua qualidade de vida e avaliar os fatores que influenciam a qualidade de vida pós-transplante renal. Metodologia. Para isso, foi realizado um estudo bibliográfico considerando fontes de bancos de dados acadêmicos como PubMed, Scopus, Web of Science, entre outros. Os descritores de busca utilizados foram "transplante renal", "qualidade de vida", "percepção do paciente", "resultados pós-transplante" Além disso, a busca foi estendida a periódicos especializados, teses, livros e congressos relacionados ao tema. Os critérios de inclusão incluíram estudos originais, revisões sistemáticas, meta-análises, publicações nos últimos 10 anos, etc. Estudos não relacionados, artigos de opinião e publicações em idiomas não acessíveis foram considerados como critérios de exclusão. Quanto ao processo de extração de informações, foram utilizadas a matriz de registro e as técnicas de observação e análise documental. A matriz foi composta por autor(es), ano de publicação, país de origem, objetivos do estudo, metodologia utilizada, variáveis analisadas, principais resultados e conclusões relevantes. Conclusões. É essencial reconhecer que a qualidade de vida pós-transplante renal é uma experiência subjetiva que varia significativamente entre os pacientes e é influenciada por uma ampla gama de fatores, que vão desde o controle dos sintomas físicos até o enfrentamento de desafios psicológicos e sociais.

Assuntos

RESUMO

el gesto altruista del donante vivo y sano de riñón, relacionado genética o sentimentalmente, se basa en autodeterminación, voluntad y generosidad. La argumentación ética alrededor de la donación de riñón de donante vivo y sano se orienta con las éticas principialista y personalista, la dignidad humana, la corporalidad, la divisibilidad del cuerpo, el mal menor y el mal mayor. Hace parte del derecho a la información amplia y suficiente que recibe el donante sobre los riesgos y posibles complicaciones físicas y morales del procedimiento, por medio del comité de bioética y el grupo de trasplantes. Con base en la argumentación ética planteada se procedió a contestar la pregunta de esta investigación: ¿se debe dejar que una persona viva y sana sea sometida a una cirugía que le dejará mononéfrico de por vida, solo por el deseo de ayudar a otro, a pesar de que existen programas activos con donante cadavérico? El objetivo de este artículo es plantear una argumentación ética sobre la donación de riñón de donante vivo y sano que contribuya a una adecuada orientación de su decisión.

the altruistic gesture of the healthy living kidney donor, genetically or sentimentally related, is based on self-determination, willingness, and generosity. The ethical argumentation around living and healthy kidney donation is guided by principled and personalistic ethics, human dignity, corporeality, divisibility of the body, the lesser evil, and the greater evil. It is part of the right to ample and sufficient information that the donor receives about the procedure's risks and possible physical and moral complications through the bioethics committee and the transplant group. Based on the ethical argumentation raised, we proceeded to answer the question of this research: should a living and healthy person be subjected to a surgery that will leave him/her mononephric for life, just because of the desire to help another, even though there are active programs with a cadaveric donor? This article aims to provide an ethical argumentation on living and healthy donor kidney donation that will contribute to an adequate orientation of their decision.

o gesto altruísta do doador de rim vivo e saudável, relacionado genética ou sentimentalmente, está baseado na autodeterminação, vontade e generosidade. A argumentação ética ao redor da doação de rim de doador vivo e saudável é orientada pelas éticas principialista e personalista, pela dignidade humana, pela corporalidade, pela divisibilidade do corpo, pelo mal menor e pelo mal maior. Faz parte do direito à informação ampla e suficiente que o doador recebe sobre os riscos e possíveis complicações físicas e morais do procedimento, por meio do comitê de bioética e do grupo de transplantes. Com base na argumentação ética proposta, procedeu-se a contestar a seguinte pergunta de pesquisa: deve-se deixar que uma pessoa viva e saudável seja submetida a uma cirurgia que a deixará mononéfrico para sempre, somente pelo desejo de ajudar o outro, apesar de existirem programas ativos com doador cadavérico? Nesse contexto, o objetivo deste artigo é apresentar uma argumentação ética sobre a doação de rim de doador vivo e saudável que contribua para uma adequada orientação de sua decisão.

RESUMO

INTRODUCTION: The age for kidney transplantation (KT) is no longer a limitation and several studies have shown benefits in the survival of elderly patients. The aim of this study was to examine the relationship of the baseline Charlson comorbidity index (CCI) score to morbidity and mortality after transplantation. METHODS: In this multicentric observational retrospective cohort study, we included patients older than 60 years admitted on the waiting list (WL) for deceased donor KT from January 01, 2006, to December 31, 2016. The CCI score was calculated for each patient at inclusion on the WL. RESULTS: Data for analysis were available of 387 patients. The patients were divided in tertiles of CCI: group 1 (CCI: 1-2) n = 117, group 2 (CCI: 3-4) n = 158, and group 3 (CCI: ≥5) n = 112. Patient survival was significantly different between CCI groups at 1, 3, and 5 years, respectively: 90%, 88%, and 84% for group 1, 88%, 80%, and 72% for group 2, and 87%, 75%, and 63% for group 3 (p < 0.0001). Variables associated with mortality were CCI score (p < 0.0001), HLA mismatch (p = 0.014), length of hospital stay (p < 0.0001), surgical complications (p = 0.048). CONCLUSION: Individualized strategies to modify these variables may improve patient's morbidity and mortality after KT.

Assuntos

RESUMO

The study aimed to investigate the impact of HLA-DPB1 allelic and molecular mismatches on the occurrence of acute rejection (AR) and low 5-year graft function (5Y-GF) in first kidney transplant (KT) recipients. This is a single center retrospective study of 130 deceased donor KT recipients transplanted between 2014 and 2016. HLA-DPB1 allelic MM and the following molecular MM (mMM) were analyzed: expression MM with the high expression G allele in the donor; T cell epitope MM (TCE MM); epitope MM (EMM), considering all six hypervariable regions (EMM-ABCDEF HVR), or only ABEF regions (EMM-ABEF HVR); eplet MM (EpMM); antibody-verified eplet MM (AbVer EpMM); and solvent accessible amino acid MM (SAMM). There was no association of allelic MM with AR or 5Y-GF. The variables independently associated (Cox regression analyses) with AR were high donor final creatinine, nonpermissive TCE MM, ABCDEF EMM load ≥6, EpMM load ≥6; SAMM load ≥5, and AbVer EpMM load ≥3. No association between any HLA-DPB1 mMM and 5Y-GF was observed when all 130 transplant recipients were considered. However, when transplants from expanded criteria donors were excluded, independent associations were detected (logistic regression analyses) with AbVerEpMM load ≥2, SAMM load ≥7, cerebro-vascular death, donor age, and AR. To our knowledge, this is the first study that shows that some HLA-DPB1 mMM are associated with AR and low 5Y-GF in a population of exclusively first kidney transplant recipients.

Assuntos

RESUMO

SUMMARY OBJECTIVE: The main objective of this study is to evaluate the rate of continuity and satisfaction with hormonal intrauterine device in renal transplant recipients. METHODS: This was a prospective observational study. The sample consisted of patients treated at a Family Planning Outpatient Clinic, from August 2016 to September 2021. Information on each patient's age, parity, and associated diseases as well as satisfaction with the method were analyzed. Patients were invited to participate through electronic messages, and the questionnaire included questions about acceptance of the contraceptive method. RESULTS: A total of 40 patients were included in the study. The mean age of the renal transplant patients was 32.5 years. The mean duration of hormonal intrauterine device use was 37 months. Acceptance of the method was high, with 97.5% of patients remaining on the method for 1 year and 85% of patients using the hormonal intrauterine device at the time of the study. There were no pregnancies or renal transplant complications in the study. Regarding satisfaction with the method, the majority (77.5%) scored 10. CONCLUSION: Patients were satisfied or very satisfied with the hormonal intrauterine device. Therefore, the continuation rate was high. Furthermore, this contraceptive method proved to be safe and effective in kidney transplant recipients. No complications, graft rejection, or graft failure were observed after intrauterine hormonal device insertion and during follow-up.

RESUMO

Introducción: El trasplante renal es uno de los métodos de sustitución de la función renal y tiene como factor de mayor influencia en su supervivencia, la compatibilidad inmunológica del sistema mayor. Objetivos: Definir la supervivencia del trasplante y su relación con el grado de compatibilidad. Métodos: Se realizó un estudio retrospectivo sobre el tiempo de supervivencia con base hospitalaria de los 512 trasplantes en el período comprendido entre los años 1993 y 2010, ambos incluidos con seguimiento y corte al concluir el año 2019. Se empleó el Kaplan Meier para calcular las supervivencias, se utilizó el paquete estadístico Statiscal Package Social Science (Spss) versión 22.0. Resultados: 397 pacientes recibieron riñones cadavéricos al momento del corte, 11,3 por ciento de los injertos estaban funcionando, mientras que para los 115 que recibieron de vivo, el 45,2 por ciento, p=0,000. La mediana de supervivencia para el cadavérico fue de 3,1 años (SD 2,4-3,8) y dentro de ellos los que compartieron tres o más antígenos lograron el doble de sobrevida, p=0,033. Para el de donante vivo, la mediana fue de 16,0 años (SD 9,1-22,9) y dentro de este grupo 104 pacientes que compartían un haplotipo lograron 44,2 por ciento de función, los hermanos que eran idénticos un 66,0 por ciento. Por parentesco los que recibieron riñones de hermanos tienen mejor supervivencias que de padres a hijos, p=0,001. Conclusiones: Se definió que la compatibilidad inmunológica del sistema mayor entre donante y receptor propicia diferencias en la función de los injertos(AU)

Introduction: Renal transplantation is one of the methods of renal function substitution and the main factor influencing survival is the immunological compatibility of the major system. Objectives: To define transplant survival and the relationship with the degree of compatibility. Methods: A retrospective study was carried out on the hospital-based survival time of 512 transplants from 1993 to 2010, including follow-up and the cut at the end of 2019. The Kaplan-Meier estimator was used to calculate the survivals, the statistical package Statistical Package Social Science (Spss) version 22.0 was used. Results: Three hundred ninety seven (397) patients received cadaveric kidneys at the cut, 11.3percent of the grafts were functioning, 115 received living grafts, 45.2percent p=0.000. The median survival for the cadaveric kidneys was 3.1 years (SD 2.4-3.8) and among them those who shared three or more antigens achieved twice the survival, p=0.033. For the living donor, the median was 16.0 years (SD 9.1-22.9) and within this group, 104 patients, sharing a haplotype, achieved 44.2percent function, siblings, who were identical, achieved 66 .0percent. By kinship, those who received kidneys from siblings have better survival than for those who received it from parents, p=0.001. Conclusions: Immunological compatibility of the major system between donor and recipient was defined to favor differences in the function of the grafts(AU)

Assuntos